VAT1L

Summary

VAT1L (vesicle amine transport 1 like, HGNC:29315) is a protein-coding gene on chromosome 16q23.1, encoding Putative NADPH-dependent quinone oxidoreductase VAT1L (Q9HCJ6). Putative NADPH-dependent quinone oxidoreductase.

Predicted to enable oxidoreductase activity and zinc ion binding activity.

Source: NCBI Gene 57687 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 82 total
• MANE Select transcript: NM_020927

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29315
Approved symbol	VAT1L
Name	vesicle amine transport 1 like
Location	16q23.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1576
Ensembl gene	ENSG00000171724
Ensembl biotype	protein_coding
OMIM	620202
Entrez	57687

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000302536, ENST00000563850

RefSeq mRNA: 1 — MANE Select: NM_020927 NM_020927

CCDS: CCDS32492

Canonical transcript exons

ENST00000302536 — 9 exons

Exon	Start	End
ENSE00000694990	77884608	77884802
ENSE00000945485	77825246	77825461
ENSE00001143322	77816921	77817050
ENSE00001203123	77971850	77971933
ENSE00001203164	77977597	77980107
ENSE00001321007	77788564	77788915
ENSE00003471666	77862748	77862890
ENSE00003563060	77879169	77879224
ENSE00003689436	77876370	77876473

Expression profiles

Bgee: expression breadth ubiquitous, 199 present calls, max score 98.14.

FANTOM5 (CAGE): breadth broad, TPM avg 9.3825 / max 497.7461, expressed in 712 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
155074	5.2135	610
155073	3.2497	583
155075	0.5665	260
155072	0.2694	158
155076	0.0833	32

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pigmented layer of retina	UBERON:0001782	98.14	gold quality
retina	UBERON:0000966	98.11	gold quality
dorsal root ganglion	UBERON:0000044	97.83	gold quality
hypothalamus	UBERON:0001898	96.31	gold quality
ventricular zone	UBERON:0003053	95.94	gold quality
cerebellum	UBERON:0002037	95.63	gold quality
cerebellar cortex	UBERON:0002129	95.53	gold quality
superior vestibular nucleus	UBERON:0007227	95.49	gold quality
cerebellar hemisphere	UBERON:0002245	95.47	gold quality
left ventricle myocardium	UBERON:0006566	95.35	gold quality
nucleus accumbens	UBERON:0001882	95.04	gold quality
cardiac muscle of right atrium	UBERON:0003379	95.01	gold quality
endothelial cell	CL:0000115	94.95	gold quality
trigeminal ganglion	UBERON:0001675	94.84	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.70	gold quality
lateral globus pallidus	UBERON:0002476	93.82	gold quality
medulla oblongata	UBERON:0001896	93.36	gold quality
cerebellar vermis	UBERON:0004720	93.36	gold quality
caudate nucleus	UBERON:0001873	93.13	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	92.85	gold quality
spinal cord	UBERON:0002240	92.81	gold quality
substantia nigra pars compacta	UBERON:0001965	92.02	gold quality
putamen	UBERON:0001874	91.90	gold quality
heart right ventricle	UBERON:0002080	91.69	gold quality
stromal cell of endometrium	CL:0002255	91.53	gold quality
pons	UBERON:0000988	90.77	gold quality
myocardium	UBERON:0002349	90.55	silver quality
islet of Langerhans	UBERON:0000006	90.50	gold quality
superior frontal gyrus	UBERON:0002661	90.29	gold quality
anterior cingulate cortex	UBERON:0009835	89.99	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-MTAB-9388	yes	13.73
E-GEOD-135922	yes	13.11
E-MTAB-5061	yes	9.23
E-GEOD-137537	yes	6.23
E-ANND-3	yes	3.91

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

156 targeting VAT1L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-1193	100.00	65.93	529
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-380-3P	99.89	70.18	1978

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	vat1l	ENSDARG00000101280
mus_musculus	Vat1l	ENSMUSG00000046844
rattus_norvegicus	Vat1l	ENSRNOG00000011989
drosophila_melanogaster	Drat	FBGN0033188
caenorhabditis_elegans		WBGENE00010790
caenorhabditis_elegans		WBGENE00010791
caenorhabditis_elegans		WBGENE00014096
caenorhabditis_elegans		WBGENE00017060

Paralogs (17): PTGR1 (ENSG00000106853), VAT1 (ENSG00000108828), TP53I3 (ENSG00000115129), MECR (ENSG00000116353), CRYZ (ENSG00000116791), RTN4IP1 (ENSG00000130347), PTGR2 (ENSG00000140043), SORD (ENSG00000140263), ADH6 (ENSG00000172955), PTGR3 (ENSG00000180011), ADH1A (ENSG00000187758), ADH7 (ENSG00000196344), ADH1B (ENSG00000196616), ADH5 (ENSG00000197894), ADH4 (ENSG00000198099), CRYZL1 (ENSG00000205758), ADH1C (ENSG00000248144)

Protein

Protein identifiers

Putative NADPH-dependent quinone oxidoreductase VAT1L — Q9HCJ6 (reviewed: Q9HCJ6)

Alternative names: Synaptic vesicle membrane protein VAT-1 homolog-like, Vesicle amine transport 1 like

All UniProt accessions (1): Q9HCJ6

UniProt curated annotations — full annotation on UniProt →

Function. Putative NADPH-dependent quinone oxidoreductase.

Tissue specificity. Detected in skin fibroblasts.

Similarity. Belongs to the zinc-containing alcohol dehydrogenase family. Quinone oxidoreductase subfamily.

RefSeq proteins (1): NP_065978* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002364	Quin_OxRdtase/zeta-crystal_CS	Conserved_site
IPR011032	GroES-like_sf	Homologous_superfamily
IPR013154	ADH-like_N	Domain
IPR020843	ER	Domain
IPR036291	NAD(P)-bd_dom_sf	Homologous_superfamily
IPR052100	VAT1	Family

Pfam: PF08240, PF13602

Catalyzed reactions (Rhea), 1 shown:

• 2 a quinone + NADPH + H(+) = 2 a 1,4-benzosemiquinone + NADP(+) (RHEA:14269)

UniProt features (52 total): strand 18, helix 15, binding site 9, modified residue 4, compositionally biased region 3, region of interest 2, chain 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
4A27	X-RAY DIFFRACTION	2.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HCJ6-F1	86.19	0.73

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (9): 217; 275; 316; 321; 372; 82; 192; 193; 214

Post-translational modifications (4): 392, 393, 395, 396

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 99 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_DN, ATGCAGT_MIR217, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_NAD_P_H, AGTCAGC_MIR345, TGCCTTA_MIR124A, LEIN_MIDBRAIN_MARKERS, ZHENG_GLIOBLASTOMA_PLASTICITY_UP, WANG_SMARCE1_TARGETS_UP, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_NAD_P_H_QUINONE_OR_SIMILAR_COMPOUND_AS_ACCEPTOR, CAGTATT_MIR200B_MIR200C_MIR429, MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3, MEISSNER_NPC_HCP_WITH_H3K4ME2_AND_H3K27ME3, MIKKELSEN_NPC_HCP_WITH_H3K27ME3, CHICAS_RB1_TARGETS_GROWING

GO Biological Process (0):

GO Molecular Function (4): zinc ion binding (GO:0008270), NADPH dehydrogenase (quinone) activity (GO:0008753), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transition metal ion binding	1
NAD(P)H dehydrogenase (quinone) activity	1
NADPH dehydrogenase activity	1
binding	1
catalytic activity	1

Protein interactions and networks

STRING

1772 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
VAT1L	CLEC3A	O75596	536
VAT1L	WWOX	Q9NZC7	501
VAT1L	SYCE1L	A8MT33	499
VAT1L	ECHDC2	Q86YB7	495
VAT1L	HIBCH	Q6NVY1	492
VAT1L	ACADVL	P49748	443
VAT1L	MAD1L1	Q9Y6D9	431
VAT1L	NUDT7	P0C024	430
VAT1L	ALDH2	P05091	429
VAT1L	MAOA	P21397	427
VAT1L	STRN4	Q9NRL3	388
VAT1L	KRT23	Q9C075	375
VAT1L	TOMM40	O96008	371
VAT1L	OSBPL3	Q9H4L5	370
VAT1L	CTNNA3	Q9UI47	366

IntAct

20 interactions, top by confidence:

A	B	Type	Score
SERPIND1	VAT1L	psi-mi:“MI:0915”(physical association)	0.590
UBXN2B	VAT1L	psi-mi:“MI:0915”(physical association)	0.560
HTT	VAT1L	psi-mi:“MI:0915”(physical association)	0.560
ST6GALNAC1	EEF1A2	psi-mi:“MI:0914”(association)	0.560
C11orf24	NME2P1	psi-mi:“MI:0914”(association)	0.530
VAT1L	PIBF1	psi-mi:“MI:0914”(association)	0.530
SLC9A6	MAP1LC3B2	psi-mi:“MI:0914”(association)	0.530
PPP1CA	ACO2	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
ATG16L1	ESYT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (15): UBXN2B (Two-hybrid), PIBF1 (Affinity Capture-MS), VAT1L (Affinity Capture-MS), VAT1L (Affinity Capture-MS), UFSP2 (Affinity Capture-MS), VAT1L (Two-hybrid), VAT1L (Affinity Capture-MS), VAT1L (Affinity Capture-MS), VAT1L (Affinity Capture-MS), PIBF1 (Affinity Capture-MS), UFSP2 (Affinity Capture-MS), VAT1L (Affinity Capture-MS), VAT1L (Affinity Capture-MS), VAT1L (Affinity Capture-MS), APP (Reconstituted Complex)

ESM2 similar proteins: A0A6N3IN21, A3KCL7, A6QQF5, B0BNC9, O35678, O75911, O77769, O88876, O97764, P00333, P05336, P11415, P14673, P14674, P14675, P17648, P28032, P47199, P50336, Q08257, Q0MVN8, Q0P5F9, Q28452, Q28GQ2, Q2R8Z5, Q3MIE4, Q3UGR5, Q3UNZ8, Q5BJJ5, Q5R4B4, Q5R4S7, Q60HD5, Q62465, Q6AYR6, Q6AYT0, Q75ZX4, Q80TB8, Q8LEB2, Q8R1Q9, Q8R238

Diamond homologs: A0A068ABB7, A0A084R1H6, A0A0B5KU17, A0A0C6E0I7, A0A0F7GFS4, A0A0M4L8I7, A0A0S6XH49, A0A0U4ZX08, A0A0U5GK88, A0A167LUQ4, A0A1L7U4V5, A0A1L9WN37, A0A1U8QN18, A0A1V6PAF7, A0A1W5T1U1, A0A2H3CTK0, A0A3T0QHT6, A0A411L027, A0A443HK66, A0A481WR96, A0A482N9V7, A0A5C1RDA3, A0A6F9DXA0, A0JJU1, A0R0B2, A2QQV0, A5ABG0, B4ER95, B4ER97, B6F209, B8NJG3, D4AU31, D9N1A1, E0D202, E0D204, E9F8M3, G0REX6, G1XU04, G3J9P0, G3JUI8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

82 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	68
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1773 predictions. Top by Δscore:

Variant	Effect	Δscore
16:77788862:G:GT	donor_gain	1.0000
16:77788863:A:T	donor_gain	1.0000
16:77788884:G:GT	donor_gain	1.0000
16:77788921:G:GG	donor_gain	1.0000
16:77813551:G:GT	donor_gain	1.0000
16:77816905:C:G	acceptor_gain	1.0000
16:77816906:A:AG	acceptor_gain	1.0000
16:77816906:ATTT:A	acceptor_gain	1.0000
16:77816907:T:G	acceptor_gain	1.0000
16:77816917:ACAGT:A	acceptor_gain	1.0000
16:77816919:A:AG	acceptor_gain	1.0000
16:77816919:AGT:A	acceptor_gain	1.0000
16:77816919:AGTG:A	acceptor_gain	1.0000
16:77816920:G:GT	acceptor_gain	1.0000
16:77816920:GT:G	acceptor_gain	1.0000
16:77816920:GTG:G	acceptor_gain	1.0000
16:77816920:GTGG:G	acceptor_gain	1.0000
16:77816920:GTGGA:G	acceptor_gain	1.0000
16:77817046:ATGAG:A	donor_loss	1.0000
16:77817047:TGAGG:T	donor_loss	1.0000
16:77817048:GAGGT:G	donor_loss	1.0000
16:77817049:AG:A	donor_loss	1.0000
16:77817050:GGTAA:G	donor_loss	1.0000
16:77817051:GTA:G	donor_loss	1.0000
16:77817052:T:A	donor_loss	1.0000
16:77825242:CCAG:C	acceptor_loss	1.0000
16:77825244:A:AG	acceptor_gain	1.0000
16:77825244:AGAT:A	acceptor_loss	1.0000
16:77825244:AGATT:A	acceptor_gain	1.0000
16:77825245:G:GG	acceptor_gain	1.0000

AlphaMissense

2764 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:77816931:T:C	F82L	0.999
16:77816933:C:A	F82L	0.999
16:77816933:C:G	F82L	0.999
16:77816995:G:A	G103E	0.999
16:77817009:G:T	G108W	0.999
16:77817010:G:A	G108E	0.999
16:77817016:T:A	V110D	0.999
16:77825285:T:A	W135R	0.999
16:77825285:T:C	W135R	0.999
16:77876456:G:A	G270E	0.999
16:77876456:G:T	G270V	0.999
16:77884668:G:T	G315W	0.999
16:77884669:G:A	G315E	0.999
16:77816930:C:A	N81K	0.998
16:77816930:C:G	N81K	0.998
16:77816938:A:T	D84V	0.998
16:77816950:G:C	R88P	0.998
16:77817003:T:C	C106R	0.998
16:77825259:T:A	V126D	0.998
16:77825288:G:C	A136P	0.998
16:77825385:C:A	A168D	0.998
16:77825433:T:A	V184E	0.998
16:77825436:T:C	L185P	0.998
16:77862749:G:A	G194D	0.998
16:77862767:T:C	L200P	0.998
16:77862771:T:G	C201W	0.998
16:77862800:G:A	G211E	0.998
16:77862819:G:C	K217N	0.998
16:77862819:G:T	K217N	0.998
16:77876401:G:C	D252H	0.998

dbSNP variants (sampled 300 via entrez): RS1000007105 (16:77799328 T>C), RS1000015984 (16:77975120 G>A,T), RS1000037090 (16:77863871 G>A,T), RS1000056056 (16:77925558 C>G,T), RS1000079881 (16:77877196 G>T), RS1000086659 (16:77925474 A>G), RS1000088502 (16:77852739 C>G,T), RS1000100721 (16:77952164 T>A,C), RS1000105306 (16:77827512 G>A), RS1000119770 (16:77788633 C>T), RS1000134600 (16:77980285 A>C), RS1000137835 (16:77916096 G>A,C,T), RS1000138121 (16:77864110 T>C,G), RS1000160765 (16:77881442 G>A), RS1000170534 (16:77939811 G>C)

Disease associations

OMIM: gene MIM:620202 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): cerebellar ataxia (MONDO:0000437), intellectual disability (MONDO:0001071)

Orphanet (2): Rare ataxia (Orphanet:102002), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST001915_37	Alzheimer’s disease (cognitive decline)	4.000000e-07
GCST008152_185	Weight	8.000000e-06
GCST008962_3	Hematology traits	5.000000e-07
GCST009359_2	LDL cholesterol levels x short total sleep time interaction (1df test)	9.000000e-06
GCST009365_4	LDL cholesterol levels x short total sleep time interaction (2df test)	1.000000e-11
GCST009365_8	LDL cholesterol levels x short total sleep time interaction (2df test)	2.000000e-10
GCST012168_8	Adiponectin levels	2.000000e-06

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004338	body weight
EFO:0009186	platelet larger cell ratio
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0004502	adiponectin measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D002524	Cerebellar Ataxia	C10.228.140.252.190; C10.597.350.090.500; C23.888.592.350.090.200
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, increases expression	7
bisphenol A	decreases expression, increases expression	3
trichostatin A	affects cotreatment, decreases expression	3
sodium arsenite	affects methylation, decreases expression	2
entinostat	increases expression, affects cotreatment	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, decreases expression, affects cotreatment	2
Temozolomide	decreases expression, affects response to substance	2
Benzo(a)pyrene	affects methylation, increases methylation	2
methylmercuric chloride	decreases expression	1
lead acetate	decreases expression	1
2,5,2’,5’-tetrachlorobiphenyl	decreases expression	1
zinc chromate	increases abundance, increases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	decreases expression, affects response to substance, increases expression, affects cotreatment	1
chromium hexavalent ion	increases abundance, increases expression	1
monomethylarsonous acid	increases expression	1
dorsomorphin	decreases expression, affects cotreatment, increases expression	1
bisphenol S	increases methylation	1
LDN 193189	increases expression, affects cotreatment	1
(+)-JQ1 compound	decreases expression	1
Decitabine	affects expression	1
Sunitinib	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Carbamazepine	affects expression	1
Carmustine	affects response to substance	1
Cisplatin	affects expression	1
Diethylhexyl Phthalate	decreases expression, increases expression	1
Doxorubicin	decreases expression	1
Estradiol	decreases expression	1

Clinical trials (associated diseases)

299 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00950196	PHASE4	COMPLETED	Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia
NCT04107740	PHASE4	COMPLETED	C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT01970098	PHASE3	COMPLETED	A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT01970111	PHASE3	COMPLETED	An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT01970124	PHASE3	COMPLETED	A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT01970137	PHASE3	COMPLETED	A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT02889302	PHASE3	COMPLETED	An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT03408080	PHASE3	ACTIVE_NOT_RECRUITING	Open Pilot Trial of BHV-4157
NCT03701399	PHASE3	ACTIVE_NOT_RECRUITING	Troriluzole in Adult Participants With Spinocerebellar Ataxia
NCT03901638	PHASE3	TERMINATED	Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy
NCT07040137	PHASE3	RECRUITING	Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT00034242	PHASE2	COMPLETED	High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration
NCT00202397	PHASE2	COMPLETED	Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia
NCT00863538	PHASE2	COMPLETED	Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT01004016	PHASE2	COMPLETED	A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
NCT01350440	PHASE2	COMPLETED	Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia
NCT02540655	PHASE2	COMPLETED	Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar Ataxia
NCT03932669	PHASE2	COMPLETED	Effect of Nilotinib in Cerebellar Ataxia Patients
NCT04301284	PHASE2	WITHDRAWN	Study of CAD-1883 for Spinocerebellar Ataxia
NCT05125666	PHASE2	UNKNOWN	Efficacy of Dual Task Training on Children With Ataxia After Medulloblastoma Resection
NCT06397274	PHASE2	NOT_YET_RECRUITING	Stemchymal® for Polyglutamine Spinocerebellar Ataxia
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT00683943	PHASE1	COMPLETED	Lithium Treatment for Patients With Spinocerebellar Ataxia Type I
NCT02287064	PHASE1	UNKNOWN	An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias
NCT05157802	PHASE1	ACTIVE_NOT_RECRUITING	Promoting Physical Activity Engagement for People With Early-stage Cerebellar Ataxia
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT01104649	PHASE2/PHASE3	COMPLETED	Efficacy of Riluzole in Hereditary Cerebellar Ataxia
NCT02960893	PHASE2/PHASE3	COMPLETED	Trial in Adult Participants With Spinocerebellar Ataxia (SCA)